Home > Keywords > Thématique > Science

Science

Articles

  • Meet Vect-Horus at TIDES Europe in Vienna from November 16th to 18th, 2022.
    16 November 2022, by Elodie DORMES

    Guillaume JACQUOT will share a presentation on “Targeted delivery of Therapeutic Oligonucleotides to CNS by systemic administration” a good opportunity for Vect-Horus to present its last results.
    Emmanuelle BETTENDORF will be there as well to assist to conferences about Emerging #Oligonuleotide Therapeutics, #Delivery Strategies for Oligonucleotides, Peptides and mRNA and meet with all actors in the field.

  • Vect-Horus participates to the event Radiopharmaceuticals & Imaging on March 14, 2023
    9 March 2023, by Elodie DORMES

    Cedric MALICET, Oncology Department Manager, will participate to the Radiopharmaceuticals & Imaging event next week ! You can book a meeting with him directly via the partnering system to discuss company developments on its theranostic agents.

  • Meet Vect-Horus at 3rd Oligonucleotides for CNS Summit in Boston June 6-8th, 2023
    30 June 2023, by Elodie DORMES

    Meet with Michel KHRESTCHATISKY and Guillaume JACQUOT at the 3rd Oligonucleotides for CNS Summit 2023, dedicated to optimizing antisense and RNA chemistry for brain delivery, in Boston from June 6-8th, 2023.

  • Two new patents protecting VECTrans® technology issued in several major countries
    28 January 2019, by Jonathan NOWAK

    Press release Communiqué de presse
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors for addressing drugs or imaging agents to the brain and other organs, announces the strengthening of its patent portfolio with the granting of two patents in several major countries and particularly in the United States.
    These two patents protect peptide vectors that facilitate the targeting of drugs or imaging agents to organs, including the brain. Entitled “Peptide (…)

  • 3rd Edition of Translational neuroscience Day : challenges and opportunities
    4 December 2019, by Elodie DORMES

    Michel KHRESTCHATISKY co-founder of Vect-Horus – Director of the UMR7051 Institute of Neurophysiopathology at Aix-Marseille University / CNRS will speak at two sessions of The third edition of “Translational neuroscience Day: challenges and opportunities” co-organized by Dhune and hosted by BioFIT on December 10, 2019.

  • Festival of Biologics 2019 in BASEL
    31 October 2019, by Elodie DORMES

    Meet with Pascaline LECORCHE during the Festival of Biologics 2019, 15 – 17 October 2019 _ Basel Switzerland and discuss on « Design of peptide-based vectors for targeted delivery ».

  • Vect-Horus demonstrates the high versatility of its peptide-vectors library for a targeted delivery of small molecules and protein cargos
    28 January 2019, by Jonathan NOWAK

    Identification and characterization of highly versatile peptide-vectors that bind non-competitively to the low-density lipoprotein receptor for in vivo targeting and delivery of small molecules and protein cargos.
    Marion David, Pascaline Lécorché, Maxime Masse, Aude Faucon, Karima Abouzid, Nicolas Gaudin, Karine Varini, Fanny Gassiot, Géraldine Ferracci, Guillaume Jacquot, Patrick Vlieghe, Michel Khrestchatisky
    http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191052 (…)

  • TIDES Europe: Oligonucleotide & Peptide Therapeutics in AMSTERDAM
    31 October 2019, by Elodie DORMES

    Dr Guillaume JACQUOT will present "Targeted Drug Delivery to the CNS and Peripheral Tissues Using the VECTrans® Innovative Technology" during the TIDES Europe, 12-15 November 2019.

  • Neurotensin, vectorised by VECT-HORUS, is the first drug-candidate in neuroprotective hypothermia
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS starts the regulatory preclinical development of VH-N439, positioned as a first-in-class neuroprotective agent in brain ischemia Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. The Company has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
    Using in vivo (…)

  • Blood Brain Barrier Summit delivered digitally
    10 August 2020, by Elodie DORMES

    Vect-Horus will assist to the Blood Brain Barrier Summit, delivered digitally from August 31 to September 2nd, 2020